Abstract
Although the current treatment of thalassemia with regular transfusions and assiduous chelation leads to a good quality of life and long survival, it is cumbersome and expensive. Various treatments have recently been explored. Bone marrow transplantation can cure thalassemia, but there was severe mortality in initial trials. It is safely successful only in patients in good clinical condition and with a compatible donor. Certain drugs, including azacytidine, butyrate, hydroxyurea, and erythropoietin may increase the production of fetal hemoglobin; their practical value is being explored. New potential oral iron chelators are under investigation. L1, the best evaluated, appears effective, but its potential toxicity remains undefined.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.